Stay updated on Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial
Sign up to get notified when there's something new on the Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial page.

Latest updates to the Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial page
- Check2 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' UI element has been removed.SummaryDifference0.2%
- Check9 days agoChange DetectedThe page has undergone a version update from v3.0.0 to v3.0.1, with the removal of the 'Results First Posted' and 'Last Update Posted' sections, which may affect the clarity of the page's update history.SummaryDifference0.2%
- Check16 days agoChange DetectedThe web page has been updated to reflect a new trial date of August 29, 2025, and includes detailed eligibility criteria and study parameters for a Phase 2 neoadjuvant study evaluating ARV-471 and anastrozole in post-menopausal women with ER+/HER2- localized breast cancer. Additionally, specific locations for the trial have been added, enhancing the clarity of the study's geographical scope.SummaryDifference63%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial page.